Compare Mesoblast Limited (MESO) vs Micron Technology, Inc. (MU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Micron Technology, Inc. — how do they compare? Mesoblast Limited trades at $16.08 (market cap $2.17B), while Micron Technology, Inc. trades at $920.98 (market cap $977.44B). The key difference: Micron Technology, Inc. is far larger — about 450.4× Mesoblast Limited's market cap, and Micron Technology, Inc. pays a 0.06% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | MU | |
|---|---|---|
Market Cap | $2.17B | $977.44B |
Sector | Technology | Technology |
52-Week High | $20.96 | $1.21K |
52-Week Low | $12.88 | $104.88 |
Enterprise Value | $2.17B | $957.80B |
Dividend Yield | — | 0.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Micron (MU) trades at $862.32, down 1.57% with a bearish technical signal, though it remains 30% below its 52-week high. The company reported strong Q3 2025 earnings of $4.78 EPS, beating expectations, with revenue surging to $37.38 billion. Analyst consensus is strongly bullish with an 81.43% buy rating and a $1,550 price target. Recent news highlights memory chip demand driven by AI, though sector-wide bear market concerns persist.
Outlook remains positive due to robust AI-driven memory demand and earnings beats, but risks include cyclical industry volatility and competitive pressures. The stock offers growth potential if it maintains execution amid high expectations, yet investors should monitor sector sentiment and guidance updates for sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →
